← Leaderboards
Eduardo N Chini
Mayo Clinic Rochester
$9,940,387
Attributed
$12,509,893
Total exposure
8
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.4M · FY2009–25$2M$1.5M$1M$500K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,509,893 · 8
By mechanism
R01$10,175,526 · 5
P50$1,557,019 · 1
R21$395,912 · 1
R56$381,436 · 1
Top collaborators
- John Varga5 shared
- Asher A Chanan-Khan4 shared
- Mirella L Meyer-Ficca1 shared
Most similar at Mayo Clinic Rochester
Same institution · by research overlap
- Tait D Shanafelt$9,008,119
- Zhenkun Lou$18,569,951
- Martin Rodriguez-Porcel$4,576,351
Others in their field
Top investigators on “Metabolism”
- David M Nathan · Massachusetts Institute Of Technology$157,845,616
- Joseph J. Eron · Univ Of North Carolina Chapel Hill$144,157,234
- Judith S. Currier · University Of California Los Angeles$141,260,706
- John M Lachin · George Washington University$139,991,329
- Randall J Bateman · Washington University$124,168,384
- Carol Nesel · Westat$116,355,411
Research focus
MetabolismMetabolicPathway InteractionsLeadEnzymesResponseMalignant NeoplasmsCellsIn VivoAnimal ModelLinkNad+ NucleosidaseIn VitroMolecularInvestigationAffectTargeted TreatmentNicotinamide Adenine DinucleotideImmuneLongevityInhibitor/AntagonistSignal TransductionAgingConsumption
Grant awards (33)
CD38 modulation of NAD metabolism driving scleroderma pathogenesis$601,753
R01 · FY2025 · AR
CD38 modulation of NAD metabolism driving scleroderma pathogenesis$648,599
R01 · FY2024 · AR
CD38 modulation of NAD metabolism driving scleroderma pathogenesis$682,658
R01 · FY2023 · AR
Therapeutic implication of CD38 in CLL$565,086
R01 · FY2023 · CA · contact PI
Therapeutic implication of CD38 in CLL$598,011
R01 · FY2022 · CA
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$344,300
R01 · FY2022 · AG · contact PI
Therapeutic implication of CD38 in CLL$610,215
R01 · FY2021 · CA
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$187,844
R01 · FY2021 · AG · contact PI
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$161,956
R01 · FY2021 · AG · contact PI
Therapeutic implication of CD38 in CLL$610,215
R01 · FY2020 · CA
NAD Metabolism in Male Reproductive Aging$381,436
R56 · FY2020 · AG
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$349,800
R01 · FY2020 · AG · contact PI
Therapeutic implication of CD38 in CLL$610,213
R01 · FY2019 · CA
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$349,800
R01 · FY2019 · AG · contact PI
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$247,755
R01 · FY2019 · AG · contact PI
Targeting NAD metabolism to treat systemic sclerosis$174,240
R21 · FY2019 · AR
Role of CD38 in NAD metabolism: from the basic biology of aging to translation$349,800
R01 · FY2018 · AG · contact PI
Targeting NAD Catabolism in Pancreatic Cancer Cells: Role of Small Molecule SIRT$332,445
P50 · FY2018 · CA · contact PI
Targeting NAD metabolism to treat systemic sclerosis$221,672
R21 · FY2018 · AR
Targeting NAD Catabolism in Pancreatic Cancer Cells: Role of Small Molecule SIRT$289,095
P50 · FY2017 · CA · contact PI
The Sir2-p53-IGF link in mammalian life-span control$348,062
R01 · FY2016 · AG · contact PI
Targeting NAD Catabolism in Pancreatic Cancer Cells: Role of Small Molecule SIRT$311,978
P50 · FY2016 · CA · contact PI
The Sir2-p53-IGF link in mammalian life-span control$343,344
R01 · FY2015 · AG · contact PI
Targeting NAD Catabolism in Pancreatic Cancer Cells: Role of Small Molecule SIRT$315,918
P50 · FY2015 · CA · contact PI
The Sir2-p53-IGF link in mammalian life-span control$353,963
R01 · FY2014 · AG · contact PI
Targeting NAD Catabolism in Pancreatic Cancer Cells: Role of Small Molecule SIRT$307,583
P50 · FY2014 · CA · contact PI
The Sir2-p53-IGF link in mammalian life-span control$336,220
R01 · FY2013 · AG · contact PI
Molecular mechanisms of fatty liver disease: role of the protein DBC1$250,093
R01 · FY2013 · DK · contact PI
The Sir2-p53-IGF link in mammalian life-span control$355,788
R01 · FY2012 · AG · contact PI
Molecular mechanisms of fatty liver disease: role of the protein DBC1$259,164
R01 · FY2012 · DK · contact PI
Molecular mechanisms of fatty liver disease: role of the protein DBC1$259,164
R01 · FY2011 · DK · contact PI
Molecular mechanisms of fatty liver disease: role of the protein DBC1$373,973
R01 · FY2010 · DK · contact PI
Molecular mechanisms of fatty liver disease: role of the protein DBC1$377,750
R01 · FY2009 · DK · contact PI